Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S. Contracts Aim To Boost Medical Emergency Readiness

by Rick Mullin
September 27, 2010 | A version of this story appeared in Volume 88, Issue 39

As part of a plan to bolster terrorism defenses, the Department of Health & Human Services’ Biomedical Advanced Research & Development Authority (BARDA) has awarded a contract to Emergent BioSolutions for the development of a recombinant protective antigen anthrax vaccine. The contract is valued at up to $187 million. It begins with a $51 million payment covering two years and includes three one-year options for continued funding, as well as a potential $9 million for nonclinical studies. BARDA recently awarded two similar contracts: one to Achaogen for the development of a novel aminoglycoside agent against plague and tularemia infections and one to Cellerant Therapeutics for the development of a cellular therapy for treating acute radiation syndrome. The awards follow a review published last month by HHS, which found that the federal medical emergency preparedness system, including BARDA, needs to do a better job nurturing early-stage discoveries and supporting innovative biotechnology firms. Meanwhile, Cleveland BioLabs won a $45 million contract from the Department of Defense to develop and stockpile CBLB502, a microbial protein derivative, as a radiation treatment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.